Amplify Weight Loss Drug & Treatment ETF THNR
Set alert
25.95 USD +0.59 +2.33%
At close · Oct 30
25.86 -0.09 -0.33%
After hours · Oct 30, 5:09 PM ET
25.81 Day range 26.01
22.95 52-week range 27.91
- YTD
- +2.88%
- 1 year
- +13.05%
- Open
- 25.81
- Prev close
- 25.36
- Mkt cap
- 5.83M
- Vol
- 1.10K
- Avg vol
- 1.27K
- EPS
- 1.22
- P/E
- 21.29
- Div yield
- 0.00%
More statistics
- Low
- 25.81
- High
- 26.01
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 24.63
- 200-d avg
- 25.88
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 31.51
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 24.63
- 200-day average
- 25.88
About Amplify Weight Loss Drug & Treatment ETF
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
News
- Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
- Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
- From Laggard to Leader: The Surprising Comeback of Healthcare
- Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
- Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September
- NTHM's Index Rebalance Puts Thematic Rotation to Work
- THNR's Weight-Loss Index Swaps Hims & Hers for Gilead
- Inside THNR: A Leaner Approach to Weight Loss Investing
- Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
- Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Your note
Sign in to keep a note on THNR — it syncs with the Stock Master app.